Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects

INTRODUCTION: Immune checkpoint inhibition (ICI) is an important treatment modality in metastatic NSCLC and management of immunotherapy-related adverse effects (irAEs) can be challenging. Retreatment after discontinuation of ICI because of irAEs is a frequent clinical dilemma with limited available...

Descripción completa

Detalles Bibliográficos
Autores principales: Lievense, Lysanne A., Heukels, Peter, van Walree, Nico C., van der Leest, Cor H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791802/
https://www.ncbi.nlm.nih.gov/pubmed/36578272
http://dx.doi.org/10.1016/j.jtocrr.2022.100441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791802/
https://www.ncbi.nlm.nih.gov/pubmed/36578272
http://dx.doi.org/10.1016/j.jtocrr.2022.100441

Ejemplares similares